Nivolumab,Ipilimumab
BMS
[]
neoadjuvant immune checkpoint inhibition in locally advanced mmr-deficient ct3/n+ colon cancer: 4% g3-4 irae 100% r0 98% timely surgery major pathologic response in 95% of patients; 67% pcr #esmo22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni